Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Market Gems:Stocks w/Strong Earnings and High Tech. Rank -- Ignore unavailable to you. Want to Upgrade?

To: Connor26 who wrote (111659)	8/11/2000 9:59:36 AM
From: Susan G	Read Replies (2) \| Respond to of 120523

Hi guys, ESPR, an IPO from yesterday is looking pretty strong today, I bought it this am. Esperion Therapeutics 6 Million Initial Shares Priced At $9 Each (Dow Jones Online News, 08/9/2000 23:10) NEW YORK -(Dow Jones)- Esperion Therapeutics Inc.'s initial public offering of 6 million shares was priced at $9 each through underwriters led by FleetBoston Financial Corp.'s (FBF) Robertson Stephens. Price talk for the IPO was $8 to $10 a share. The 6 million shares will constitute 25% of Esperion's 24 million outstanding shares. Esperion, based in Ann Arbor, Mich., plans to use proceeds to further develop and commercialize its product candidates, for ongoing research and development, payments under licensing agreements and general corporate and working capital purposes. Gross spread is 63 cents, selling concession is 37 cents and reallowance is 10 cents. Delivery is scheduled for Aug. 15. Esperion discovers and develops pharmaceutical products that treat cardiovascular disease. -Ralph Tasgal; Dow Jones Newswires; 201-938-5400